Vaxcyte, Inc.
PCVX
$44.70
-$0.82-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 75.00M |
| Gross Profit | -- | -- | -- | -- | -75.00M |
| SG&A Expenses | 125.70M | 116.24M | 105.68M | 92.90M | 81.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 811.56M | 709.11M | 635.87M | 569.55M | 604.05M |
| Operating Income | -811.56M | -709.11M | -635.87M | -569.55M | -604.05M |
| Income Before Tax | -657.20M | -547.50M | -509.63M | -463.93M | -507.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -657.20 | -547.50 | -509.63 | -463.93 | -507.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -657.20M | -547.50M | -509.63M | -463.93M | -507.65M |
| EBIT | -811.56M | -709.11M | -635.87M | -569.55M | -604.05M |
| EBITDA | -799.80M | -698.62M | -626.91M | -562.54M | -599.03M |
| EPS Basic | -4.84 | -4.11 | -3.98 | -3.80 | -4.55 |
| Normalized Basic EPS | -3.02 | -2.57 | -2.49 | -2.37 | -2.84 |
| EPS Diluted | -4.84 | -4.11 | -3.98 | -3.80 | -4.55 |
| Normalized Diluted EPS | -3.02 | -2.57 | -2.49 | -2.37 | -2.84 |
| Average Basic Shares Outstanding | 543.12M | 530.62M | 511.84M | 487.84M | 455.17M |
| Average Diluted Shares Outstanding | 543.12M | 530.62M | 511.84M | 487.84M | 455.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |